EMA Flags Faulty Generic Drug Data, Backs Sales Halt
Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz
Phase 2 of HIPAA Audit Program Launches
U.S. Senate Moves Closer to Confirming Califf to Lead FDA
U.S. & EU Regulators Urge Indian Drug Companies to Step Up Standards
Federal Compliance Mandates for Medical Practices
